FDA grants accelerated approval to first drug for Duchenne m
Aditya Bhatt
FDA grants accelerated approval to first drug for Duchenne muscular dystrophy
The U.S. Food and Drug Administration today approved Exondys 51 (eteplirsen) injection, the first drug approved to treat patients with Duchenne muscular dystrophy (DMD). Exondys 51 is specifically indicated for patients who have a confirmed mutation of the dystrophin gene amenable to exon 51 skipping, which affects about 13 percent of the population with DMD.

more info- http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/UCM521263?source=govdelivery&utm_medium=email&utm_source=govdelivery
D●●●i T●●●●r and 23 others like this
Like
Comment
Share
Dr. S●●●y S●●●●●●i
Dr. S●●●y S●●●●●●i General Medicine
Sir how about others patients with other exon mutation? Wont it work on any othet than 51?
Sep 20, 2016Like
A●●●●a B●●●t
A●●●●a B●●●t General Medicine
No this only works on exon 15 skipping so it is not indicated for everyone but only specific ones
Sep 20, 2016Like
Dr. S●●●y S●●●●●●i
Dr. S●●●y S●●●●●●i General Medicine
I would like to ask about the role of gentamycine in DMD ! If anyone can update or have knowledge about that
Sep 20, 2016Like